Kilitch Drugs (India) Valuation
Is 524500 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524500?
Other financial metrics that can be useful for relative valuation.
|What is 524500's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 524500's PE Ratio compare to its peers?
|524500 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
532989 Bafna Pharmaceuticals
532637 Mangalam Drugs & Organics
526953 Venus Remedies
540694 ANG Lifesciences India
524500 Kilitch Drugs (India)
Price-To-Earnings vs Peers: 524500 is expensive based on its Price-To-Earnings Ratio (32.3x) compared to the peer average (21.1x).
Price to Earnings Ratio vs Industry
How does 524500's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 524500 is expensive based on its Price-To-Earnings Ratio (32.3x) compared to the Indian Pharmaceuticals industry average (23.7x)
Price to Earnings Ratio vs Fair Ratio
What is 524500's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||32.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524500's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 524500 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 524500's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 524500's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.